Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye test may forecast kidney failure after cancer surgery

NCT ID NCT04855123

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether special eye scans (OCT-angiography) can predict how well the remaining kidney will work one year after kidney removal for cancer. Researchers enrolled 30 adults scheduled for total nephrectomy. The goal was to see if retinal blood vessel patterns could warn of kidney function decline. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward a non-invasive way to predict kidney failure after kidney removal, helping doctors choose the best surgery type.
What could go wrong
This trial was terminated early and enrolled only 30 people, so results are limited. The link between retinal changes and kidney function is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Mar 2021

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient * Indication for total nephrectomy for kidney cancer decided with a multidisciplinary oncology consultation * Kidney scan images available * Patient affiliated to French national health insurance * Patient who has given oral consent Exclusion Criteria: * Pregnant woman * Ophthalmologic history (macular vascular or degenerative diseases, epiretinal membranes, glaucoma) * Cannot sit still for 60 minutes * Metastatic cancer * Single functional kidney before nephrectomy * Estimated Glomerular Filtration Flow Rate (CKD-EPI formula) less than 60 mL/min/1.73m2 * Diabetes type 1 or type 2 * Proteinuria at inclusion (or in the 3 months prior to inclusion) on sample with a protein/creatinuria ratio greater than 1g/g or over 24 hours greater than 1g/day * HIV, HCV or HBV positive serology * Patient subject to a measure of legal protection (guardianship, curatorship, etc.) SECONDARY EXCLUSION CRITERIA * Patient with increased pressure during the measurement of the intraocular pressure before dilation * Patient with histological abnormalities suggestive of nephropathy (excluding nephroangiosclerosis) or ischemic parenchymal sequelae of renal vein thrombosis in the pathological analysis of the nephrectomy sample

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease kidney cancer retinal vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nephrostomy Retinal vascularisation

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.